Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers

Next Previous
Trial Profile

A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Casdatifan (Primary) ; Midazolam
  • Indications Cancer; Liver cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Arcus Biosciences

Most Recent Events

  • 25 Oct 2024 Results evaluating pharmacokinetic profile of AB521 presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
  • 29 Mar 2024 Results (n=55) developing a population PK model describing the relationship between dose and AB521 PK, identify influential covariates of AB521 PK presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 21 Feb 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top